Show results for
Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
T Cell Receptor Based Cell Therapy Suppliers In Usa
15 companies found
based in, NEW JERSEY (USA)
Tevogen Bio is driven by a team of distinguished scientists and experienced biopharmaceutical leaders who have developed and commercialized multiple franchises. In collaboration with key strategic partners, the company moved its lead product from ...
Innovative Science in Virology, Oncology, and Neurology; Allogeneic CD8+ T cell therapies from a single donor to treat thousands for the first ...
based inMarlborough, MASSACHUSETTS (USA)
Cytiva, now with the life sciences business from Pall, is a global provider of technologies, services, and expertise to help researchers and companies protect and preserve the planet for improved human health and safety. Our products offer quality, ...
based inMont-Saint-Guibert, BELGIUM
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. We are developing a diversified pipeline of allogeneic and autologous CAR T cell ...
based inBerlin, GERMANY
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the ...
based inSherman Oaks, CALIFORNIA (USA)
T-Cure is a clinical-stage immuno-oncology company developing the next generation of T cell therapies for patients with solid tumors. It is committed to bringing new targets and therapies to the T-Cell Receptor (TCR) field that have a high ...
T cell engineering with TCRs is a growing area of immuno-oncology with recent breakthroughs in clinical settings. The T-Cure approach involves identifying and isolating a high avidity TCR which specifically recognizes an intracellular or ...
based inCarlsbad, CALIFORNIA (USA)
TargaZyme is a clinical-stage biotechnology company based in San Diego, CA and focused on the research and development of disruptive and novel, off-the-shelf T-Cell products that are aimed at improving the efficacy of T-cell therapies by delivering ...
TILs are part of the body’s natural response to cancer:The cells of the immune system perform immunosurveillance while circulating throughout the bodyAs part of the normal immune response, TIL migrate to the tumor site through recognition of ...
based inSan Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune ...
based inNew York, NEW YORK (USA)
IN8bio was founded in 2016 with the mission of developing novel therapies to address cancer. The company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product ...
INB-200, our DeltEx DRI, is a genetically modified autologous gamma-delta T cell product candidate for the treatment of solid tumors. This is the first genetically engineered gamma-delta T cell therapy to be administered to patients and our initial ...
based inSouth San Francisco, CALIFORNIA (USA)
We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of cancer. Our proprietary technology is designed to harness the power of these important pathogen-fighting immune cells and is uniquely capable of enhancing ...
based inBerkeley, CALIFORNIA (USA)
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell ...
CAR-T cell therapies are a class of treatments in which T cells are modified to express chimeric antigen receptors (CARs). CARs are engineered molecules that, when present on the surface of a T cell, enable a T cell to recognize a specific protein ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
based inPhiladelphia, PENNSYLVANIA (USA)
A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases Cabaletta Bio seeks to employ its specifically targeted CAAR (Chimeric AutoAntibody Receptor) T ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical investigators continue to focus on the ...